Skip to content
★ Sign in to follow
Shanghai OPM Biosciences Co., Ltd. logo

Shanghai OPM Biosciences Co., Ltd. Stock: price and insider trades · China

奥浦迈

CN·Mcap CN¥8.6BHealth Care

No insider purchase over the last 90 days. The latest, by 肖志华, was filed 25 Dec 2024.

Shanghai OPM Biosciences Co., Ltd.: what insiders have been doing

Shanghai OPM Biosciences Co., Ltd., classified in the Health Care sector, is a listed company. Its insiders report their share dealings to SSE / SZSE (CSRC). No insider at Shanghai OPM Biosciences Co., Ltd. has published a filing in the past twelve months. The most recent one dates from 25 December 2024.

Over the whole record (from 2023), the tally stands at 24 purchases and no sales.

Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and Vetoquinol SA. Source: insider filings from SSE / SZSE (CSRC). Past trades are no guide to future returns.

Insider Decl.
24
Thresholds
n/a
Buy Volume
€1M
24 ops. · all time
Sell Volume
n/a
n/a

Who traded when

BuySale
肖志华1 buy

Since the insiders bought

  • Filed 25 Dec 2024 · 685 days ago · €52k
    +39.2%
    Entry CN¥37.58 · Close at T+365 CN¥52.32
  • Filed 09 Jul 2024 · 854 days ago · €3,827
    +71.2%
    Entry CN¥27.28 · Close at T+365 CN¥46.69

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Fundamental score
Ranked 12,973 of 26,911 companies
52.4
score / 100
Value
38
Quality
67
FCF yld0.6%
Earn yld0.5%
EV/EBITDA·
ROE4.8%
Gross mgn51%
Net mgn12%
Debt/EBITDA0.6x
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

CN¥60.20
Analyst consensus
·
Income statement
RevenueCN¥354.9M
Gross profitCN¥180.5M51% margin
EBITDACN¥102.5M29% margin
Net incomeCN¥41.7M20.3% margin
Valuation
PER (trailing)122.9x
P/Book2.7x
Beta0.57
Balance sheet & cash
Market capCN¥8.6B
Total debtCN¥57M
Free Cash FlowCN¥47.3M
Debt / Equity8%
Profitability & ownership
ROE4.8%
ROA1.0%
% insiders30.9%
% institutions28.7%
Last declaration on 25 December 2024
Declarations24 total
  • ▲
    董事,高级管理人员Executives
    399,866 CNY7SSE
    10,545 shares4.0% of flowA股XSHGSSE:173000008375556300
    Canonical exit: 25 Mar 2025 (T+90)
  • ▲
    董事,高级管理人员Executives
    30,008 CNY9SSE
    1,111 shares16.7% of flowA股XSHGSSE:173000007827567700
    Canonical exit: 7 Oct 2024 (T+90)
  • ▲
    董事,高级管理人员Executives
    29,610 CNY9SSE
    1,000 shares16.5% of flowA股XSHGSSE:173000007815776030
    Canonical exit: 2 Oct 2024 (T+90)
  • ▲
    董事Executives
    756,489 CNY20SSE
    20,412 shares7.2% of flowA股XSHGSSE:173000007648737900
    Canonical exit: 14 Aug 2024 (T+90)
  • ▲
    董事Executives
    36,670 CNY9SSE
    1,000 shares20.6% of flowA股XSHGSSE:173000007635109600
    Canonical exit: 11 Aug 2024 (T+90)
  • ▲
    董事Executives
    499,810 CNY19SSE
    12,712 shares4.9% of flowA股XSHGSSE:173000007383578620
    Canonical exit: 10 Jun 2024 (T+90)
  • ▲
    董事Executives
    596,500 CNY20SSE
    15,062 shares5.8% of flowA股XSHGSSE:173000007376623460
    Canonical exit: 6 Jun 2024 (T+90)
  • ▲
    董事Executives
    870,959 CNY20SSE
    21,027 shares8.5% of flowA股XSHGSSE:173000007374381440
    Canonical exit: 5 Jun 2024 (T+90)
  • ▲
    董事Executives
    44,020 CNY9SSE
    1,000 shares24.9% of flowA股XSHGSSE:173000007364704670
    Canonical exit: 3 Jun 2024 (T+90)
  • ▲
    董事Executives
    449,879 CNY19SSE
    11,984 shares4.4% of flowA股XSHGSSE:173000007299810720
    Canonical exit: 2 May 2024 (T+90)
  • ▲
    董事Executives
    37,380 CNY21SSE
    1,000 shares21.3% of flowA股XSHGSSE:173000007296143400
    Canonical exit: 1 May 2024 (T+90)
  • ▲
    董事Executives
    449,867 CNY7SSE
    11,485 shares4.4% of flowA股XSHGSSE:173000007293204200
    Canonical exit: 30 Apr 2024 (T+90)
  • ▲
    董事Executives
    449,842 CNY7SSE
    11,099 shares4.4% of flowA股XSHGSSE:173000007286997730
    Canonical exit: 28 Apr 2024 (T+90)
  • ▲
    董事Executives
    499,853 CNY7SSE
    12,153 shares4.9% of flowA股XSHGSSE:173000007280179780
    Canonical exit: 25 Apr 2024 (T+90)
  • ▲
    董事Executives
    499,915 CNY7SSE
    11,974 shares4.9% of flowA股XSHGSSE:173000007272441950
    Canonical exit: 22 Apr 2024 (T+90)
  • ▲
    董事Executives
    299,856 CNY7SSE
    6,593 shares2.9% of flowA股XSHGSSE:173000007258690780
    Canonical exit: 16 Apr 2024 (T+90)
  • ▲
    董事Executives
    529,840 CNY8SSE
    10,201 shares5.1% of flowA股XSHGSSE:173000007219043840
    Canonical exit: 4 Apr 2024 (T+90)
  • ▲
    董事Executives
    835,252 CNY8SSE
    15,588 shares8.1% of flowA股XSHGSSE:173000007216702200
    Canonical exit: 3 Apr 2024 (T+90)
  • ▲
    董事Executives
    554,325 CNY8SSE
    10,208 shares5.4% of flowA股XSHGSSE:173000007176934700
    Canonical exit: 19 Mar 2024 (T+90)
  • ▲
    董事Executives
    569,854 CNY8SSE
    10,102 shares5.5% of flowA股XSHGSSE:173000007172551580
    Canonical exit: 17 Mar 2024 (T+90)
  • ▲
    董事Executives
    599,886 CNY8SSE
    10,543 shares5.8% of flowA股XSHGSSE:173000007117323840
    Canonical exit: 22 Feb 2024 (T+90)
  • ▲
    董事Executives
    501,800 CNY7SSE
    10,000 shares5.0% of flowA股XSHGSSE:173000007009663400
    Canonical exit: 16 Jan 2024 (T+90)
  • ▲
    董事Executives
    458,600 CNY7SSE
    10,000 shares4.5% of flowA股XSHGSSE:173000006933251620
    Canonical exit: 13 Dec 2023 (T+90)
  • ▲
    董事Executives
    453,100 CNY7SSE
    10,000 shares4.3% of flowA股XSHGSSE:173000006688385280
    Canonical exit: 27 Sept 2023 (T+90)

24 of 24 declarations

About Shanghai OPM Biosciences Co., Ltd.

奥浦迈 is a company operating in the healthcare and pharmaceutical sector, listed on the Shanghai Stock Exchange. It focuses on the development and commercialization of innovative pharmaceutical products.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations